MAIN GROUPS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS: MECHANISMS OF ACTION AND CLINICAL EFFICACY. PART 2

Vrach ◽  
2021 ◽  
Vol 32 (4) ◽  
pp. 31-37
Author(s):  
A. Chaulin ◽  
N. Svechkov ◽  
S. Volkova
Keyword(s):  
Clinical Efficacy ◽  
Mechanisms Of Action ◽  
Proprotein Convertase

Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy

2007 ◽  
Vol 1117 (1) ◽  
pp. 209-257 ◽  
Author(s):  
R. G. G. RUSSELL ◽  
Z. XIA ◽  
J. E. DUNFORD ◽  
U. OPPERMANN ◽  
A. KWAASI ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Mechanisms Of Action

Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

2012 ◽  
Vol 142 (1) ◽  
pp. 15-24 ◽  
Author(s):  
Jens Ingwersen ◽  
Orhan Aktas ◽  
Patrick Kuery ◽  
Bernd Kieseier ◽  
Alexey Boyko ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Efficacy ◽  
Mechanisms Of Action

Specific immunotherapy: clinical efficacy and mechanisms of action

1992 ◽  
Vol 26 ◽  
pp. 46-47 ◽  
Author(s):  
E.A. Pastorello ◽  
C. Incorvaia ◽  
C. Zanussi
Keyword(s):  
Clinical Efficacy ◽  
Specific Immunotherapy ◽  
Mechanisms Of Action

scholarly journals How Do Tumor-Treating Fields Work?

2020 ◽  
pp. 19-35
Author(s):  
Kristen W. Carlson ◽  
Jack A. Tuszynski ◽  
Socrates Dokos ◽  
Nirmal Paudel ◽  
Thomas Dreeben ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Clinical Efficacy ◽  
Brain Cancer ◽  
Mechanisms Of Action ◽  
Great Promise ◽  
Tumor Treating Fields ◽  
Cancer Types

AbstractSince approved by the FDA for the treatment of glioblastoma brain cancer in 2015, tumor-treating fields (TTFields) have rapidly become the fourth modality to treat cancer, along with surgery, chemotherapy, and radiation [1]. TTFields are now in clinical trials for a variety of cancer types. While efficacy has been proven in the clinic, the higher efficacy is demonstrated in vitro and in animal models, which indicates much greater clinical efficacy is possible. To attain the great promise of TTFields, uncovering the mechanisms of action (MoA) is necessary.

scholarly journals The use of innovative domestic interferon inducer for the prevention and treatment of acute respiratory viral infections in children

2016 ◽  
Vol 1 (1) ◽  
pp. 50-53 ◽  
Author(s):  
Y. L. Mizernitskiy
Keyword(s):  
Clinical Efficacy ◽  
Viral Infections ◽  
Mechanisms Of Action ◽  
Efficacy And Safety ◽  
Interferon Inducer ◽  
Interferon Inducers ◽  
Treatment And Prevention ◽  
Prevention And Treatment ◽  
Respiratory Viral Infections

The article presents data on the place of the modern endogenous interferon inducers in the treatment and prevention of influenza and ARVI in children and the mechanisms of action. The focus is on the domestic antiviral innovation Kagocel which demonstrated high clinical efficacy and safety in a number of multi-center, blind, placebo-controlled studies of the treatment and prevention of ARVI/flu in children over 2 years old.

Sign in / Sign up

Export Citation Format

Share Document